VERSI GROUP LLC has a total of 15 patent applications. It decreased the IP activity by 40.0%. Its first patent ever was published in 2002. It filed its patents most often in United States, EPO (European Patent Office) and Canada. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are AFFERENT PHARMACEUTICALS INC, MITHRIDION INC and SABRE THERAPEUTICS LLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 6 | |
#2 | EPO (European Patent Office) | 4 | |
#3 | Canada | 2 | |
#4 | WIPO (World Intellectual Property Organization) | 2 | |
#5 | Australia | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Heterocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Chang Kwen-Jen | 7 |
#2 | Pendergast William | 7 |
#3 | Versi Ebrahim | 7 |
#4 | Biciunas Kestutis P | 6 |
#5 | Jan Shyi-Tai | 4 |
#6 | Reidenberg Bruce | 4 |
#7 | King Klim | 4 |
#8 | Mcnutt Robert W | 4 |
#9 | Gengo J Peter | 2 |
#10 | Holt Jonathon D S | 1 |
Publication | Filing date | Title |
---|---|---|
CA3061323A1 | An opioid for use to reduce and/or treat drug addiction | |
WO2017173067A1 | Delta opioid agonist, mu opioid antagonist compositions and methods for treating parkinson's disease | |
EP1450807A1 | Method of treating depression with delta receptor agonist compounds |